Table 2.
Polymorphism | Genotype (n) | Frequency (Hardy-Weinberg) | Paraoxon (units/ml) | Phenylacetate (units/ml) |
---|---|---|---|---|
n | 331 | 144 | 144 | |
p.Leu53Met | LL (135) | 0.40 (0.39) | 77.8 (46.2–106.5) | 73.4 (64.9–87.7) |
ML (149) | 0.45 (0.46) | 39.1 (28.4–64.7) | 66.2 (53.0–80.9) | |
MM (47) | 0.14 (0.13) | 21.0 (16.7–30.4) | 56.0 (39.5–63.0) | |
P value | <0.001 | <0.001 | ||
p.Gln191Arg | RR (29) | 0.09 (0.08) | 99.8 (73.0–185.0) | 68.2 (32.2–85.8) |
RQ (127) | 0.38 (0.39) | 80.3 (63.4–106.1) | 68.7 (54.6–80.1) | |
QQ (175) | 0.53 (0.52) | 30.5 (24.5–39.8) | 66.7 (53.1–81.7) | |
P value | <0.001 | 0.81 | ||
c.-107C>T* | CC (90) | 0.27 (0.26) | 61.4 (37.9–90.3) | 77.4 (68.4–90.2) |
CT (154) | 0.49 (0.49) | 40.3 (28.7–82.3) | 70.3 (59.4–81.6) | |
TT (75) | 0.24 (0.24) | 34.6 (20.8–73.6) | 54.0 (39.7–63.2) | |
P value | 0.017 | <0.001 |
Data are median (interquartile range) unless otherwise indicated.
For c.-107C>T, genotyping was performed in 319 individuals and PON1 activity measured in 139 subjects.